TY - JOUR
T1 - Gamma sensory entrainment for cognitive improvement in neurodegenerative diseases
T2 - opportunities and challenges ahead
AU - Sahu, Prangya Parimita
AU - Tseng, Philip
N1 - Funding Information:
This study was supported by funding from Taiwan’s National Sciences and Technology Counsel to PT (MOST 106-2410-H-038-005-MY2, MOST 108-2410-H-038-009, and NSTC 109-2423-H-006-003-MY4).
Publisher Copyright:
Copyright © 2023 Sahu and Tseng.
PY - 2023
Y1 - 2023
N2 - Neural oscillations have been categorized into various frequency bands that are mechanistically associated with different cognitive functions. Specifically, the gamma band frequency is widely implicated to be involved in a wide range of cognitive processes. As such, decreased gamma oscillation has been associated with cognitive declines in neurological diseases, such as memory dysfunction in Alzheimer’s disease (AD). Recently, studies have attempted to artificially induce gamma oscillations by using 40 Hz sensory entrainment stimulation. These studies reported attenuation of amyloid load, hyper-phosphorylation of tau protein, and improvement in overall cognition in both AD patients and mouse models. In this review, we discuss the advancements in the use of sensory stimulation in animal models of AD and as a therapeutic strategy in AD patients. We also discuss future opportunities, as well as challenges, for using such strategies in other neurodegenerative and neuropsychiatric diseases.
AB - Neural oscillations have been categorized into various frequency bands that are mechanistically associated with different cognitive functions. Specifically, the gamma band frequency is widely implicated to be involved in a wide range of cognitive processes. As such, decreased gamma oscillation has been associated with cognitive declines in neurological diseases, such as memory dysfunction in Alzheimer’s disease (AD). Recently, studies have attempted to artificially induce gamma oscillations by using 40 Hz sensory entrainment stimulation. These studies reported attenuation of amyloid load, hyper-phosphorylation of tau protein, and improvement in overall cognition in both AD patients and mouse models. In this review, we discuss the advancements in the use of sensory stimulation in animal models of AD and as a therapeutic strategy in AD patients. We also discuss future opportunities, as well as challenges, for using such strategies in other neurodegenerative and neuropsychiatric diseases.
UR - https://www.scopus.com/pages/publications/85159924410
UR - https://www.scopus.com/inward/citedby.url?scp=85159924410&partnerID=8YFLogxK
U2 - 10.3389/fnint.2023.1146687
DO - 10.3389/fnint.2023.1146687
M3 - Short survey
AN - SCOPUS:85159924410
SN - 1662-5145
VL - 17
JO - Frontiers in Integrative Neuroscience
JF - Frontiers in Integrative Neuroscience
M1 - 1146687
ER -